Brickell Biotech to Host Key Opinion Leader Webinar on DYRK1A and its Role in Autoimmunity streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Single-Cell Insights on Inaccessible Tumor Environments Expand Therapeutic Options
Patient with melanoma leptomeningeal metastasis [Keiran Smalley/The Moffitt Cancer Center]
June 3, 2021
Share
While melanoma, a form of skin cancer that begins in the pigmented cells of the skin (melanocytes), is less common than other types of skin cancer, its seriousness lies in its ability to spread to other organs if not treated at an early stage. In nearly 75% patients, autopsy reveals the metastasis of melanoma to the central nervous system (CNS).
Of these, patients with the worst prognosis and rapid disease progression are those in whom melanoma spreads to the leptomeninges, the two innermost layers of the meninges that cover and protect the brain (leptomeningeal melanoma metastases, LMM).
Press release content from Business Wire. The AP news staff was not involved in its creation.
IMV’s Lead Immunotherapy to be Investigated in Breast Cancer
May 10, 2021 GMT
DARTMOUTH, Nova Scotia (BUSINESS WIRE) May 10, 2021
IMV Inc. (Nasdaq: IMV; TSX: IMV) (“IMV” or the “Company”), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies, today announced that its lead compound, maveropepimut-S (DPX-Survivac) will be investigated in patients with hormone receptor positive/HER2-negative (HR+/HER2-) breast cancer. HR+/HER2- tumors represent an unmet clinical need with relatively poor responses to neoadjuvant endocrine treatment 1. This investigator-initiated clinical study will be conducted at the Providence Cancer Institute in Portland, Oregon, and is expected to begin during summer 2021.
According to the New York Blood Center analysis, the vaccines create enough antibodies to fight the disease
Published March 17, 2021 •
Updated on March 17, 2021 at 12:43 pm
NBC Universal, Inc.
What to Know
All three of the FDA-approved vaccines against COVID-19 show efficacy against the mutated strains of the virus, according to an analysis by the New York Blood Center (NYBC) published in
Science Magazine.
NYBC found that the Pfizer, Johnson & Johnson, and Moderna vaccines create enough antibodies to fight the virus variants, according to the article “Vaccine efficacy probable against COVID-19 variants” by Dr. Christopher D. Hillyer and Dr. Larry Luchsinger.
However, according to the published analysis, the efficacy of vaccines need to be reexamined as new strains emerge.
Newly discovered biochemical pathway can protect cells from ferroptosis
The hallmarks of cancer include rapid cell-reproduction and metabolic activity. But these processes also lead to increased cellular stress and oxidation, and the risk of cell death.
To circumvent these negative consequences of supercharged growth, cancer cells stimulate pathways to reduce oxidative stress and avoid cell death. In an article published in
Cell Metabolism, Moffitt Cancer Center researchers report on a newly discovered biochemical pathway that protects cells from a type of cell death called ferroptosis.
Ferroptosis is a specialized type of cell death that is caused by imbalances in oxidation within cells. Ferroptosis results in changes to molecules in the cell membrane called lipids and can be caused by cysteine starvation.